Organization Overview
Alternative names
acetylsalicylic acid (aspirin) (1 trial)
aripiprazole (abilify) (2 trials)
chlorpromazine (Thorazine) (1 trial)
cisplatin (platinol) (18 trials)
eltrombopag (promacta) (3 trials)
entecavir (baraclude) (2 trials)
etomidate (amidate) (2 trials)
etoposide (vepesid) (7 trials)
fluticasone (cutivate) (4 trials)
gemcitabine (gemzar) (5 trials)
irinotecan (Camptosar) (5 trials)
levothyroxine (Synthroid) (1 trial)
olanzapine (zyprexa) (2 trials)
pegaspargase (oncaspar) (2 trials)
propofol (diprivan) (2 trials)
131i-lipiodol (Lipiodol) (1 trial)
albuterol (proventil) (2 trials)
cetuximab (erbitux) (2 trials)
cyclophosphamide (cytoxan) (13 trials)
cytarabine (cytosar-u) (1 trial)
decitabine (dacogen) (1 trial)
docetaxel (taxotere) (13 trials)
doxycycline (vibramycin) (1 trial)
epirubicin (ellence) (8 trials)
Filgrastim (neupogen) (1 trial)
fluorouracil (efudex) (8 trials)
methylprednisolone (medrol) (1 trial)
omacetaxine (synribo) (1 trial)
oxaliplatin (eloxatin) (8 trials)
paclitaxel (taxol) (21 trials)
pemetrexed (alimta) (6 trials)
pertuzumab (perjeta) (3 trials)
pomalidomide (pomalyst) (1 trial)
porfimer (photofrin) (1 trial)
atezolizumab (Tecentriq) (1 trial)
autologous tumor infiltrating lymphocytes (1 trial)
bevacizumab (avastin) (5 trials)
bortezomib (velcade) (2 trials)
cytokine induced killer cells (2 trials)
dacarbazine (dtic-dome) (1 trial)
doxorubicin (Doxil) (4 trials)
durvalumab (imfinzi) (1 trial)
fludarabine (fludara) (6 trials)
fruquintinib (Fruzaqla) (2 trials)
fulvestrant (faslodex) (1 trial)
lapatinib (tykerb) (14 trials)
lenalidomide (revlimid) (4 trials)
lenvatinib (lenvima) (2 trials)
mitoxantrone (novantrone) (1 trial)
monosialic gangliosides (2 trials)
oxycodone (oxycontin) (1 trial)
autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)
autologous cytokine induced killer cells (1 trial)
autologous dendritic cells (1 trial)
autologous mesenchymal stem cell-derived neural progenitors (1 trial)
car19 t cells carrying cytoplasmic activated pd-1 (1 trial)
acitretin (soriatane) (1 trial)
autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells (1 trial)
beclomethasone (vanceril) (1 trial)
Adenocarcinoma (Phase 3)
Adenocarcinoma of Lung (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Cerebral Infarction (Phase 4)
Chronic Disease (Phase 3)
Cognitive Dysfunction (Phase 2)
Colorectal Neoplasms (Phase 3)
Communicable Diseases (Phase 2)
Compulsive Personality Disorder (Phase 2)
Disease (Phase 3)
Dwarfism, Pituitary (Phase 4)
Endocrine System Diseases (Phase 4)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Fibrosis (Phase 4)
Glioma (Phase 2)
Graves Ophthalmopathy (Phase 3)
Heart Failure (Phase 4)
Heart Neoplasms (Phase 3)
Hemophilia A (Phase 3)
Hepatitis (Phase 4)
Hepatitis A (Phase 4)
Hepatitis B (Phase 4)
Hepatitis B, Chronic (Phase 4)
Hepatitis, Chronic (Phase 4)
Hodgkin Disease (Phase 2)
Hypersensitivity (Phase 2)
Hypertension (Phase 3)
Hypothyroidism (Phase 4)
Infections (Phase 2)
Infertility (Phase 4)
Infertility, Female (Phase 4)
Intestinal Neoplasms (Phase 2)
Ischemia (Phase 4)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 1)
Leukemia, Large Granular Lymphocytic (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, T-Cell (Phase 3)
Liver Cirrhosis (Phase 4)
Lung Diseases (Phase 3)
Lung Diseases, Obstructive (Phase 4)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 4)
Melanoma (Phase 2)
Menopause, Premature (Phase 2)
Multiple Myeloma (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nausea (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Plasma Cell (Phase 2)
Neuroendocrine Tumors (Phase 2)
Neurotoxicity Syndromes (Phase 2)
Obsessive-Compulsive Disorder (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Parkinson Disease (Phase 1)
Premature Birth (Phase 2)
Primary Ovarian Insufficiency (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Purpura (Phase 2)
Purpura, Thrombocytopenic (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 4)
Recurrence (Phase 3)
Renal Artery Obstruction (Phase 4)
Sarcoma (Phase 4)
Schizophrenia (Phase 4)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 4)
Stroke (Phase 4)
Thrombocytopenia (Phase 4)
Tic Disorders (Phase 3)
Tics (Phase 3)
Tonsillitis (Phase 4)
Tourette Syndrome (Phase 3)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Vomiting (Phase 2)
Wounds and Injuries (Phase 3)